Indaptus Therapeutics (INDP) Shares Outstanding (2020 - 2026)
Indaptus Therapeutics (INDP) posted quarterly Shares Outstanding (Entity) of $11.0 million for Q1 2026, up 1813.52% year-over-year from $572590.0 in Q1 2025, and up 1034.08% quarter-over-quarter from $966124.0 in Q4 2025.
Indaptus Therapeutics (INDP) Shares Outstanding (2020 - 2026) Analysis & Trends
Indaptus Therapeutics' Shares Outstanding (Entity) history runs 7 years deep, the most recent figure standing at $11.0 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 1813.52% year-over-year to $11.0 million; the TTM figure through Mar 2026 stood at $11.0 million (up 1813.52% YoY), while the FY2025 annual figure was $966124.0, up 189.18% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $11.0 million, up from $966124.0 in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $11.0 million in Q1 2026, with the low at $294914.0 in Q1 2022.
- The 5-year median for Shares Outstanding (Entity) is $304924.0 (2024), against an average of $1.0 million.
- The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Entity) soared 756089.74% in 2022, then changed 0.0% in 2023.
- Indaptus Therapeutics' Shares Outstanding (Entity) stood at $300001.0 in 2022, then changed by 0.0% to $300001.0 in 2023, then increased by 11.36% to $334092.0 in 2024, then surged by 189.18% to $966124.0 in 2025, then jumped by 1034.08% to $11.0 million in 2026.
- Business Quant data shows INDP's Shares Outstanding (Entity) at $11.0 million in Q1 2026, $966124.0 in Q4 2025, and $997038.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Indaptus Therapeutics | 146.91 Mn | 135.35 Mn | - | 116.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 116.13 Mn |
| Mar 31, 2026 | 10.96 Mn |
| Dec 31, 2025 | 966,124.00 |
| Sep 30, 2025 | 997,038.00 |
| Jun 30, 2025 | 574,923.00 |
| Mar 31, 2025 | 503,596.00 |
| Dec 31, 2024 | 334,092.00 |
| Sep 30, 2024 | 339,618.00 |
| Jun 30, 2024 | 305,103.00 |
| Mar 31, 2024 | 301,477.00 |
| Dec 31, 2023 | 300,001.00 |
| Sep 30, 2023 | 300,001.00 |
| Jun 30, 2023 | 300,001.00 |
| Mar 31, 2023 | 300,001.00 |
| Dec 31, 2022 | 295,040.00 |
| Sep 30, 2022 | 294,914.00 |
| Jun 30, 2022 | 294,914.00 |
| Mar 31, 2022 | 294,914.00 |
| Dec 31, 2021 | 146,075.00 |
| Sep 30, 2021 | 149,294.00 |